Esperion Therapeutics ESPR Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's operating income?
- Esperion Therapeutics (ESPR) reported operating income of -$6.58M in Q1 2026.
- How has Esperion Therapeutics's operating income changed year-over-year?
- Esperion Therapeutics's operating income increased by 70.2% year-over-year, from -$22.1M to -$6.58M.
- What is the long-term trend for Esperion Therapeutics's operating income?
- Over 4 years (2021 to 2025), Esperion Therapeutics's operating income has grown at a -28.2% compound annual growth rate (CAGR), from -$226.73M to $60.27M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.